HCell Product Pipeline
HCell Inc. is focusing on development of medical hair restoration for both men and women. HCell currently has two products in the pipeline.
|
HC017AA
|
HC017AA is focused on treating Alopecia Areata in pediatric patients. U.S. FDA has granted Orphan Drug Designation (ODD) to HC017AA for the treatment of pediatric patients with alopecia areata, a devastating hair loss disease. ODD from the FDA’s recognition gives HCell a number of potential financial benefits and is aligned with our ongoing work seeking expedited pathways towards FDA product approval in the U.S.
|
|
HC0100
|
HC0100 is focused on treating Androgenic Alopecia for both men and women. HC0100 has been tested on over 500 patients in South Korea where data supports positive results amongst these patients.
|
|
IP/Patents
|
To protect our innovation, HCell has secured U.S. and South Korea patents for both composition and methodology. HCell also has pending patent applications in many strategic countries.
|